Introduction
Neurosurgical procedures, such as resection of meningiomas or aneurysm clipping, might involve rapid and massive blood loss. The decision to measure the haemoglobin (Hb) level, and on the basis of the results obtained, when to transfuse blood, is important and crucial. A sample of the patient's blood may be sent to the laboratory which allows Hb to be measured using various methods, or the Hb value may be obtained by arterial blood gas (ABG) analysis (aHb) in the operating room. Until recently, these invasive monitoring methods were the only ones available to assess Hb levels at intermittent intervals. This required clinicians to make a decision about the timing of sampling on the basis of clinical conditions. However, a new device, Radical-7® Pulse Co-oximeter (SpHb®), (Masimo, Irvine, USA), is now available that not only allows Hb concentrations to be monitored continuously, but also non-invasively. 1 This device displays immediate and ongoing changing Hb levels, and may help the clinician to determine when a patient's Hb needs to be measured invasively. In our study, we aimed to compare Hb levels obtained using non-invasive techniques (SpHb®), with those derived using invasive methods.
Method
This study was conducted after approval from our institutional ethics committee (Ref: IEC/NP-250/2011, 2 November 2011). American Society Anesthesiologists physical status grade I and II adult patients of either sex, undergoing general anaesthesia for neurosurgical procedures, were included in the study. Patients were excluded if they refused to provide consent to participate in the study, or if they had peripheral vascular disease, haemoglobinopathy and sickle cell disease. Informed written consent was obtained from participants, who then underwent a detailed pre-anaesthetic examination.
Patients fasted for eight hours before the scheduled surgery, and received premedication with glycopyrrolate 0.2 mg intramuscularly, one hour prior to surgery. Anaesthesia was induced with fentanyl 2 mg/kg and propofol 1.5-2 μg/ kg. Tracheal intubation was facilitated with rocuronium 1 mg/kg. Isofl urane (0.8-1.2 minimum alveolar concentrations) in a mixture of O 2 and N 2 O (1:2) was used for the maintenance of anaesthesia, together with fentanyl 1 μg/kg, as an intermittent bolus to maintain analgesia. Vecuronium 0.15 mg/ kg was used intermittently to provide neuromuscular blockade. All of the patients received mannitol 1 g/kg 30 minutes before opening the duramater. Intravenous fl uids (crystalloid and/ or colloids) were administered to replace the estimated fl uid defi cit. Randomly, at any point of time during the surgery, blood samples were collected for Hb estimation from the arterial blood gas (ABG) machine (aHb), and laboratory (tHb), using an automated Hb analyser. Simultaneously, the Hb reading from the SpHb® was recorded. Other values displayed on the monitor, such as the perfusion index (PI) and methaemoglobin (metHb), were also recorded. PI is a calculated value that is displayed with the SpHb® because obtaining SpHb® values with a PI < 1.4 is not recommended by the manufacturer. Also, the blood oxygen saturation values from the standard used pulse oximeter (SpO 2 ), SpHb® (SpO 2 ) and arterial blood gas (SO 2 ) were noted at the same point of time.
Data analysis was performed using SPSS® 17. Statistical analysis summarised the distribution of observed diff erences using means, medians and ranges. Following the approach recommended by Bland and Altman, 2 owing to the possibility of within-individual correlation between successive measurements, standard deviation (SD) was estimated using mixed-effect, linear regression models. 2 Statistical significance was achieved when the p-value was less than 0.05. The Bland-Altmann plot shows the relationship between observed differences (between values obtained from two diff erent methods) and the mean of two measures. Horizontal lines correspond to the limits of agreement, and each dot represents individual values. The limits of agreement between the two methods were calculated as the mean ± 2 SD of the diff erences between the results obtained. If the diff erences are normally distributed, 95% of the diff erences between the methods lie between these limits, and the two methods can be used interchangeably if these diff erences are not clinically important. 3
Results
Thirty patients participated in the study. However, the data for only 22 patients was analysed, the PI was less than 1.4 in eight patients (values of Hb obtained with a PI of less than 1.4 are not recommended by the manufacturer). Our primary outcome variables were the SpHb®-tHb and SpHb®-aHb differences. Table 1 shows the patient characteristics. Table 2 shows the PI, metHb, Hb values (SpHb®, laboratory and ABG) and blood oxygen saturation (pulse oximeter, SpHb® and ABG) for individual patients. The mean Hb concentration was 11.4 g/dl, 10.59 g/dl and 10.4 g/dl, using the SpHb®, laboratory and ABG, respectively. MetHb values were also measured, which were in the range of (1.4-3.3%) , and the PI varied between 1.5 and 9.8. Table 3 shows the correlation between the paired samples. Figure 1 displays the Bland-Altmann plot of the relationship between the observed diff erences between aHb and SpHb® (ABG-SpHb®) and the mean of the two measures. Limits of agreement (horizontal lines) indicate that 21 of the 22 estimates of SpHb® were within the limits. The limits of agreement are defi ned as the mean diff erence ± 2 SD, and the calculated lower and upper limits for aHb-SpHb® are between −3.7 to +3.6. Figure 2 displays the Bland-Altmann plot of the relationship between observed diff erences between tHb and SpHb® (laboratory-Radical-7® Pulse Co-oximeter) and the mean of the two measures. Limits of agreement (horizontal lines) indicate that 21 of the 22 estimates of SpHb® were within the limits (−4.7 to +3). Figure 3 displays the Bland-Altmann plot of 
Discussion
The fi ndings of our study suggest that, although the noninvasive monitor provided continuous and immediate Hb values, currently, it is unable to replace invasive Hb monitoring techniques. Based on the results of the Bland-Altman plots, the two methods can be used interchangeably if the diff erences fall between the 95% confi dence interval (CI) of the diff erence, and if the diff erences are not clinically important. In this study, the calculated 95% CI for the difference calculated on the sample (ABG analysis and SpHb®) was −3.7 to 3.6. Therefore, a measurement might really be 10 mg/dl, but could be reported to be low as 6.3 mg/dl or as high as 13.6 mg/dl. This is undoubtedly a clinically important diff erence, and hence making decisions for blood transfusions based on these results would not be acceptable. The same is true for the diff erence between SpHb® and the laboratory Hb values. This wide variation may be either owing to the small sample size of the study, or to a variation in the accuracy of the non-invasive ABG: arterial blood gas, aHb: haemoglobin estimation by the ABG method, SD: standard deviation, SpHb®: Radical-7® Pulse Co-oximeter 
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SpHB®: Radical-7® Pulse Co-oximeter; R 2 = 0.3 monitor. However, the inaccuracy of SpHb® was the most likely explanation as the Hb values obtained from ABG analysis demonstrated good correlation with the laboratory values in same patients.
Moreover, in 8 out of 30 patients enrolled in the study, the Hb values were not obtained using the non-invasive monitor, a major limitation thereof. This further questions the clinical utility of this device. There are several variables that could have infl uenced the diff erences found between the non-invasive SpHb® and tHb (laboratory) measurements. Peripheral perfusion at the site of the measurement of SpHb® might have infl uenced the detection of Hb levels. The function of the SpHb® sensor depends on adequate blood fl ow to the fi nger, as indirectly refl ected by the PI. The PI is a calculated value that is displayed together with the SpHb®, because obtaining SpHb® values with a PI < 1.4 is not recommended by the manufacturer. 1 When perfusion diminishes, SpHb® underestimates true Hb, so it should not be used to determine the need for blood transfusions without validation using a direct (invasive) measurement method. 1 As perfusion improves, the SpHb® becomes a more accurate measurement methodology. Therefore, the PI is as useful a clinical guide, as is the actual SpHb® measurement. 1 In our study, we excluded patients who had a PI less than 1.4. In this study, we found poor correlation ( Table 3 and Figures 4 and 5 ) between the non-invasive (SpHb®) and invasive methods (laboratory and ABG). The correlation coeffi cient between the SpHb® and laboratory values was 0.553, and that between the SpHb® and arterial blood gas analysis values was 0.634, as against the laboratory and arterial blood gas analysis values, which had good correlation (a correlation co-effi cient of 0.97). The correlation value close to 0.5 showed virtually no correlation. Nelson's syndrome was detected in one sample in which Hb determination by SpHb® was fairly high (18 g/dl) in comparison to the Hb values from the laboratory and ABG method. The SpHb® values in this sample did not lie within the limits of correlation. However, the laboratory and arterial gas blood analysis values correlated well in this patient. This might partly explain the poor correlation between the noninvasive and invasive techniques.
Hahn et al 4 recently published the results of a study using the SpHb® (version 7.4.0.9), with a repeated-use probe that lasts for 60 hours. The authors concluded that non-invasive continuous Hb monitoring (SpHb®) could not provide useful kinetic data in individuals during volume loading. In addition, two other recent works that assessed the same device reported controversial results on the accuracy of this device. 4, 5 Specifi cally, an inverse relationship was found between the pulse-oximeter saturation (SpO 2 ) value and bias in the SpHb® measurement in one study. 6 A recent pilot study assessed the relationship between the fraction-of-inspired oxygen (FiO 2 ) and SpHb®, as indicated by the SpHb®. 7 While patients received 100% oxygen via a facemask, FiO 2 , SpO 2 and SpHb® were continuously recorded until the end-expiratory oxygen fraction was > 90%. Thereafter, anaesthesia was initiated. The mean SpHb® between FiO 2 at 21%, and FiO 2 at 100%, increased in four patients, decreased in two and remained stable in two, resulting in an overall signifi cant increase of SpHb® during pre-oxygenation (nonlinear, mixed-eff ect model). There was no change in volume or blood mass. 7 Preliminary evidence from studies in non-obstetric surgical patients indicates that the mean difference in SpHb® to aHb is approximately 1 g/dl. 5, 8, 9 Butwick et al 10 reported that SpHb® values from the SpHb® were higher than laboratory Hb concentrations in 16/17 venous and arterial blood samples. Despite a signifi cant correlation between SpHb® and laboratory Hb values (r = 0.90), they suspected that this device overestimated SpHb® values as median SpHb® values were signifi cantly higher than laboratory Hb values. With further improvements in technology, we may be able to gain better insight into the relationship between perfusion, acute changes in Hb and intravascular volume through the performance of this non-invasive monitor, and in future, non-invasive Hb monitor (SpHb®) may become the standard monitor of care for assessing patients at risk of bleeding, and also to guide transfusion therapy. 1 On the basis of the fi ndings in this study, we propose that the SpHb® does not have suffi cient accuracy to minimise the need for invasive Hb monitoring, and could not be used eff ectively in eight out of 30 (27%) patients because of low PI due to poor perfusion.
